Targeted delivery of atorvastatin via asialoglycoprotein receptor (ASGPR).
Bioorg Med Chem
; 27(11): 2187-2191, 2019 06 01.
Article
em En
| MEDLINE
| ID: mdl-31005367
ABSTRACT
Targeted drug delivery platforms can increase the concentration of drugs in specific cell populations, reduce adverse effects, and hence improve the therapeutic effect of drugs. Herein, we designed two conjugates by installing the targeting ligand GalNAc (N-acetylgalactosamine) onto atorvastatin (AT). Compared to the parent drug, these two conjugates, termed G2-AT and G2-K-AT, showed increased hepatic cellular uptake. Moreover, both conjugates were able to release atorvastatin, and consequently showed dramatic inhibition of ß-hydroxy-ß-methylglutaryl-CoA (HMG-CoA) reductase and increased LDL receptors on cell surface.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Acetilgalactosamina
/
Inibidores de Hidroximetilglutaril-CoA Redutases
/
Receptor de Asialoglicoproteína
/
Atorvastatina
Limite:
Animals
/
Humans
Idioma:
En
Ano de publicação:
2019
Tipo de documento:
Article